Showing 881-890 of 1093 results for "".
- Dr. Paul M. Friedman Named New ASLMS Presidenthttps://modernaesthetics.com/news/dr-paul-m-friedman-named-new-aslms-president/2473244/Paul M. Friedman, MD is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Friedman, board-certified by the American Board of Dermatology, is the director of Dermatology & Laser Surgery Center of Houston
- Colorescience Finishing Touch Protocol Boosts Patient Satisfaction after Microneedling RFhttps://modernaesthetics.com/news/colorescience-finishing-touch-protocol-boosts-patient-satisfaction-after-microneedling-rf/2473243/Colorescience’s Finishing Touch post-treatment skincare protocol improves patient confidence, comfort, satisfaction, and increases the likelihood of a repeat radiofrequency microneedling procedure, according to research in The Journal of Clinical and Aesthetic Dermatology
- Rion Aesthetics Initiates Series Ahttps://modernaesthetics.com/news/rion-aesthetics-initiates-series-a/2473241/With the initiation of Series A funding, Rion Aesthetics presents a unique investment opportunity for aesthetic providers. Rion plans on closing the Series A in the second quarter of 2022. Rion, a regenerati
- Evolus Celebrates Third Anniversary of the Launch of Jeuveauhttps://modernaesthetics.com/news/evolus-celebrates-third-anniversary-of-the-launch-of-jeuveau/2473239/Evolus, Inc. is celebrating the three-year anniversary of the launch of its flagship neurotoxin product, Jeuveau (prabotulinumtoxinA-xvfs), the first neurotoxin dedicated exclusively to aesthetics. Jeuveau is used for the temporary improvement in the appearance of moderate to severe ve
- Cynosure Receives $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://modernaesthetics.com/news/cynosure-recieves-60-million-follow-on-investment-from-clayton-dubilier-rice/2473237/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its cust
- ISHRS Survey: Surgical Advances; Improvements in Efficiency Driving Need for Fewer Hair Transplant Treatmentshttps://modernaesthetics.com/news/ishrs-survey-surgical-advances-improvements-in-efficiency-driving-need-for-fewer-hair-transplant-treatments/2473235/According to results of a new member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), 68 percent of members reported performing an average of one procedure per patient in 2021 to achieve the desired hair restoration result. This represents a significant improveme
- CellFX from Pulse Biosciences Shows Durable Effects for Sebaceous Hyperplasia: ASLMS Presentationhttps://modernaesthetics.com/news/cellfx-from-pulse-biosciences-shows-durable-effects-for-sebaceous-hyperplasia-aslms-presentation/2473233/The CellFX® system from Pulse Biosciences, Inc. demonstrates durable efficacy for the clearance of Sebaceous Hyperplasia lesions, according to data presented at the 2022
- Coming This Week: Cutera AviClear Webinarhttps://modernaesthetics.com/news/coming-this-week-cutera-aviclear-webinar/2473230/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn
- Elevai Labs Names Chief Marketing and Brand Advisorhttps://modernaesthetics.com/news/elevai-labs-names-chief-marketing-and-brand-advisor/2473228/Brenda Buechler is now Chief Marketing and Brand Advisor for Elevai Labs, Inc. Elevai is a science-based aesthetic skincare company providing topical formulations featuring by ethically sourced, human umbilical mesenchymal stem cells (hUMSC)-derived e
- Revance News: FDA Accepts BLA Resubmission for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-news-fda-accepts-bla-resubmission-for-daxibotulinumtoxina/2473223/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont